Does ENZALUTAMIDE Cause Gait inability? 156 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 156 reports of Gait inability have been filed in association with ENZALUTAMIDE (Xtandi). This represents 0.3% of all adverse event reports for ENZALUTAMIDE.
156
Reports of Gait inability with ENZALUTAMIDE
0.3%
of all ENZALUTAMIDE reports
32
Deaths
66
Hospitalizations
How Dangerous Is Gait inability From ENZALUTAMIDE?
Of the 156 reports, 32 (20.5%) resulted in death, 66 (42.3%) required hospitalization, and 1 (0.6%) were considered life-threatening.
Is Gait inability Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ENZALUTAMIDE. However, 156 reports have been filed with the FAERS database.
What Other Side Effects Does ENZALUTAMIDE Cause?
Fatigue (8,891)
Death (6,680)
Malignant neoplasm progression (4,696)
Prostatic specific antigen increased (3,731)
Asthenia (3,589)
Drug ineffective (3,468)
Hot flush (3,144)
Decreased appetite (3,069)
Nausea (2,898)
Dizziness (2,776)
What Other Drugs Cause Gait inability?
ADALIMUMAB (3,844)
ETANERCEPT (2,710)
METHOTREXATE (2,559)
TOFACITINIB (2,227)
SECUKINUMAB (2,216)
TOCILIZUMAB (2,139)
LEFLUNOMIDE (2,065)
RITUXIMAB (2,028)
ABATACEPT (2,019)
HYDROXYCHLOROQUINE (1,881)
Which ENZALUTAMIDE Alternatives Have Lower Gait inability Risk?
ENZALUTAMIDE vs EPCORITAMAB
ENZALUTAMIDE vs EPCORITAMAB-BYSP
ENZALUTAMIDE vs EPERISONE
ENZALUTAMIDE vs EPHEDRINE
ENZALUTAMIDE vs EPINASTINE